Cerus Corporation (NASDAQ:CERS) Announces Amended Growth Capital Deal

Cerus Corporation (NASDAQ:CERS) reported that it has finalized a $40 million amended growth capital agreement with Oxford Finance LLC, a firm that offers senior debt to healthcare services and life sciences firms globally. Under the amended facility, the company obtained an immediate loan of $30 million at closing on July 2017 and has the alternative to get another $10 million conditional on achieving a mentioned revenue milestone.

The details

Kevin D. Green, the VP, Finance and CFO of Cerus, reported that Oxford Finance continues to be a significant partner. Their appreciation of their business prospects and shared belief in their objective to grow INTERCEPT as the standard of care treatment for transfused blood components internationally strengthens their association. The non-dilutive capital and prospective access to additional proceeds offers them with financial flexibility to assist them execute on their commercial growth plan, and to support key clinical plans.

Green added that a part of the proceeds from the preliminary $30 million loan were utilized to repay the due term loans of around $17.6 million offered under the original deal with Oxford. The amended facility offers Cerus with additional capital as well as deferred amortization for around 18 to 24 months.

Christopher A. Herr of Oxford Finance reported that they are delighted to extend their association with Cerus in attempt of its commercial growth measures. The company’s commitment to enhancing patient care, proprietary technology and its seasoned management team offers them with a remarkable lending opportunity.

Cerus is a biomedical products firm focused in the segment of blood transfusion safety. Its INTERCEPT Blood System is intended to lessen the risk of transfusion-transmitted infections by disabling a broad range of pathogens like bacteria, parasites and viruses that may be existent in donated blood. The company sells and markets the INTERCEPT Blood System for plasma as well as platelets in the U.S., Europe, the Middle East, the Commonwealth of Independent States and selected nations in other regions across the globe.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Van Bettauer

Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https://plus.google.com/100770875710593766367/posts